Symbols

LSTA

Lisata Therapeutics·NASDAQ

--(--)

LSTA fundamentals

LSTA Q3 2025 Earnings

Lisata Therapeutics (LSTA) released its earnings on Nov 6, 2025: revenue was 0 (YoY --), met estimates; EPS was -0.49 (YoY +16.95%), beat estimates.

Revenue / YoY

EPS / YoY

-0.49

+16.95%

Report date

Nov 6, 2025

LSTA Earnings Call Summary for Q3,2025

Financial Stability: Operating expenses down 17.3% YoY to $4.4 million; $19M cash runway to Q1 2027.
Clinical Momentum: ASCEND trial Cohort A shows 4 complete responses; CENDIFOX pancreatic cancer resection rate 50%.
Strategic Expansion: Catalent ADC partnership with preclinical success; GATC AI drug discovery alliance identifies 2026 candidates.
Phase III Challenges: ASCEND Phase III funding requires pharma partners; stock underperformance despite positive data.

Earnings

EPS

Revenue

Revenue & Expenses

LSTA has released its 2025 Q4 earnings report, with revenue of 100.00K, reflecting a YoY change of -90.00%, and net profit of -2.95M, showing a YoY change of 35.92%. The Sankey diagram below clearly presents LSTA's revenue sources and cost distribution.

Key Indicators

Lisata Therapeutics (LSTA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Lisata Therapeutics (LSTA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Lisata Therapeutics (LSTA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Lisata Therapeutics (LSTA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown